Search Results
304 Results Found for “cardiovascular risk”
Dr Jonathan Piccini discusses rhythm control in patients with atrial fibrillation and heart failure with preserved ejection fraction, the growing role of catheter ablation, and the evidence still needed to define its impact on cardiovascular outcomes.
At ESC Congress 2026, Dr Rami Abu Fanne (Hillel Yaffe Medical Center and Hadassah Medical Center, The Hebrew University of Jerusalem) presented an analysis exploring whether baseline vitamin D levels were associated with metabolic response to semaglutide in people with type 2 diabetes. The study included 5,300 adults and found that higher baseline vitamin D levels were associated with greater improvements in glycemic control and BMI after 12 months of treatment, although no association was observed with lipid outcomes. Dr Abu Fanne spoke to touchCARDIO about the findings and the questions they raise for future research.
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1 High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2 Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and ...
AMUNDSEN showed that immediate initiation of evolocumab after myocardial infarction substantially increased LDL-C goal achievement, but did not significantly reduce death or cardiovascular hospitalization at 1 year. Starting evolocumab immediately after myocardial infarction (MI) more than doubled the proportion of patients ...
Phase III SHASTA-3 and SHASTA-4 results showed substantial and sustained triglyceride reductions with plozasiran, alongside fewer acute pancreatitis events.
The first dedicated ESC Guidelines on the management of cardiovascular disease and chronic kidney disease recommend kidney function and urine albumin testing in all patients with cardiovascular disease, with an emphasis on identifying CKD early and initiating effective treatment without delay.
Direct oral anticoagulant (DOAC) therapy reduced adverse clinical events compared with no anticoagulation in patients with atrial fibrillation (AF) at intermediate risk of stroke, according to results from the SINGLE-AF trial presented during a Hot Line session at ESC Congress 2026.1
New heart failure guidelines, practice-changing Hot Line data, artificial intelligence and new evidence in atrial fibrillation and cardiac amyloidosis are among the highlights to look out for on the opening day of ESC Congress 2026.
ESC Congress 2026 begins in Munich on August 28, bringing four days of new cardiovascular research, clinical guidance and discussion. Early data released ahead of the meeting provide a first look at some of the science to come.
Dr Arasi Maran explores practical strategies for integrating lifestyle interventions into the management of complex coronary artery disease, including how to prioritise modifiable risk factors, communicate recommendations effectively and support sustained behaviour change. She also discusses the role of imaging, reliable health information and patient-centred approaches to improving adherence.
Late-breaking clinical research will once again be a major focus at ESC Congress 2026, taking place in Munich, Germany, from August 28–31. This year, a record 59 trials have been selected for presentation across 12 Hot Line sessions, spanning new pharmacological approaches, diagnostic strategies, devices, imaging and digital technologies.
New clinical guidelines, late-breaking trials, artificial intelligence, and an increasing focus on cardiometabolic and precision medicine are set to shape discussions at ESC Congress 2026 in Munich.
Arrowhead Pharmaceuticals, Inc. (Pasadena, CA) has reported topline results from two phase III trials evaluating plozasiran in adults with severe hypertriglyceridemia (sHTG), according to a recent press release.1 Plozasiran, an siRNA therapy directed against apolipoprotein C-III (APOC3) messenger RNA, is already approved as Redemplo for adults with familial chylomicronemia syndrome but remains investigational for the broader sHTG population.
The FDA has approved enlicitide (LIPFENDRA®; Merck, Rahway, NJ, USA) tablets, 20 mg, as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), according to a press release from Merck.1 Enlicitide is a novel macrocyclic peptide and the first FDA-approved oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for lowering LDL-C.
Longer diagnosis-to-ablation time (DAT) was associated with a higher risk of atrial arrhythmia recurrence following de novo radiofrequency catheter ablation (RFA) for atrial fibrillation (AF), according to a prospective, multicenter cohort study published in JAMA Network Open.1
A proteomic analysis presented as late-breaking research at ENDO 2026 found that treatment with lorundrostat was associated with reductions in several circulating biomarkers linked to heart failure risk in patients with uncontrolled hypertension.
Long-term consumption of sugar-sweetened beverages and fruit juice, beginning in childhood, was associated with a higher likelihood of hypertension in adulthood, according to findings published in Circulation.
The American Heart Association (AHA), American College of Cardiology (ACC), American Diabetes Association (ADA) and American Society of Nephrology (ASN) have issued a new joint clinical practice guideline for the prevention, detection, evaluation and management of cardiovascular-kidney-metabolic (CKM) syndrome.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
